{"id":40308,"date":"2025-08-28T15:40:41","date_gmt":"2025-08-28T07:40:41","guid":{"rendered":"https:\/\/flcube.com\/?p=40308"},"modified":"2025-08-28T15:40:41","modified_gmt":"2025-08-28T07:40:41","slug":"innovent-biologics-revenue-soars-50-in-h1-2025-oncology-growth-fuels-glp%e2%80%911-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40308","title":{"rendered":"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion"},"content":{"rendered":"\n<p>China-based\u00a0Innovent Biologics, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) on Aug. 28, 2025 released its semi\u2011annual financial results for the first half of 2025. The company generated <strong>RMB\u202f5,953.1\u202fmillion<\/strong> in revenue, a <strong>50.6\u202f%<\/strong> year\u2011on\u2011year increase, and posted a net profit of <strong>RMB\u202f834.3\u202fmillion<\/strong>, a sharp turnaround from the previous period\u2019s deficit.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-highlights\">Financial Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>H1\u202f2025<\/th><th>YoY % Change<\/th><\/tr><\/thead><tbody><tr><td>Total Revenue<\/td><td>RMB\u202f5,953.1\u202fm<\/td><td>+50.6\u202f%<\/td><\/tr><tr><td>Product Revenue<\/td><td>RMB\u202f5,233.8\u202fm<\/td><td>+37.3\u202f%<\/td><\/tr><tr><td>License Fee Income<\/td><td>RMB\u202f665.6\u202fm<\/td><td>+\u2014 (Roche upfront)<\/td><\/tr><tr><td>Net Profit<\/td><td>RMB\u202f834.3\u202fm<\/td><td>\u2014 (from loss)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-portfolio-expansion\">Product Portfolio Expansion<\/h3>\n\n\n\n<p>Innovent\u2019s product line grew to <strong>16<\/strong> items, adding <strong>five<\/strong> new launches during the reporting period:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology<\/strong><\/li>\n\n\n\n<li><strong>DOVBLERON<\/strong> (taletrectinib)<\/li>\n\n\n\n<li><strong>limertinib<\/strong> (EGFR\u2011TKI)<\/li>\n\n\n\n<li><strong>Jaypirca<\/strong> (pirtobrutinib)<\/li>\n\n\n\n<li><strong>General Biomedicine<\/strong><\/li>\n\n\n\n<li><strong>SYCUME<\/strong> (teprotumumab N01)<\/li>\n\n\n\n<li><strong>mazdutide<\/strong> (GLP\u20111\/GLP\u2011G dual agonist)<\/li>\n<\/ul>\n\n\n\n<p>Two investigational candidates are now under NDA review:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IBI112<\/strong> (picankibart, IL\u201123p19 antibody) \u2013 moderate\u2011to\u2011severe plaque psoriasis<\/li>\n\n\n\n<li><strong>IBI310<\/strong> (ipilimumab N01) + <strong>TYVYT<\/strong> (sintilimab) \u2013 neoadjuvant therapy for MSI\u2011H\/dMMR colon cancer<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-licensing-and-partnerships\">Strategic Licensing and Partnerships<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Roche Collaboration<\/strong> \u2013 Generated a significant upfront fee, boosting license\u2011income and reinforcing Innovent\u2019s position in the oncology arena.<\/li>\n\n\n\n<li><strong>Pipeline Momentum<\/strong> \u2013 The addition of GLP\u20111\/GLP\u2011G dual\u2011agonist mazdutide signals a strategic pivot toward metabolic disease, complementing the company\u2019s oncology strength.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-outlook\">Outlook<\/h3>\n\n\n\n<p>With a solid cash position and a growing product slate, Innovent is poised to sustain its revenue momentum, deepen its oncology portfolio, and accelerate the commercialization of its GLP\u20111\u2011based therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082700861_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025082700861_c.\"><\/object><a id=\"wp-block-file--media-007bff8e-edf9-4ea3-a6d4-0a3ea13a93fd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082700861_c.pdf\">2025082700861_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082700861_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-007bff8e-edf9-4ea3-a6d4-0a3ea13a93fd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based\u00a0Innovent Biologics, Inc. (HKG: 1801) on Aug. 28, 2025 released its semi\u2011annual financial results for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40310,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[30,27,910,198],"class_list":["post-40308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biotech","tag-finanical-reports","tag-hkg-1801","tag-innovent-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011listed Innovent\u202fBiologics (HKG:\u202f1801) posted a 50.6\u202f% YoY revenue jump to RMB\u202f5.95\u202fbn in the first half of 2025, powered by oncology sales and the launch of its GLP\u20111 dual\u2011agonist mazdutide. The company added five new products, secured a lucrative Roche license fee, and turned a loss into a RMB\u202f834\u202fm profit.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40308\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion\" \/>\n<meta property=\"og:description\" content=\"China\u2011listed Innovent\u202fBiologics (HKG:\u202f1801) posted a 50.6\u202f% YoY revenue jump to RMB\u202f5.95\u202fbn in the first half of 2025, powered by oncology sales and the launch of its GLP\u20111 dual\u2011agonist mazdutide. The company added five new products, secured a lucrative Roche license fee, and turned a loss into a RMB\u202f834\u202fm profit.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40308\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T07:40:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2809.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion\",\"datePublished\":\"2025-08-28T07:40:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308\"},\"wordCount\":238,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2809.webp\",\"keywords\":[\"Biotech\",\"Finanical Reports\",\"HKG: 1801\",\"Innovent Biologics\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40308#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40308\",\"name\":\"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2809.webp\",\"datePublished\":\"2025-08-28T07:40:41+00:00\",\"description\":\"China\u2011listed Innovent\u202fBiologics (HKG:\u202f1801) posted a 50.6\u202f% YoY revenue jump to RMB\u202f5.95\u202fbn in the first half of 2025, powered by oncology sales and the launch of its GLP\u20111 dual\u2011agonist mazdutide. The company added five new products, secured a lucrative Roche license fee, and turned a loss into a RMB\u202f834\u202fm profit.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40308\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2809.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2809.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40308#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011listed Innovent\u202fBiologics (HKG:\u202f1801) posted a 50.6\u202f% YoY revenue jump to RMB\u202f5.95\u202fbn in the first half of 2025, powered by oncology sales and the launch of its GLP\u20111 dual\u2011agonist mazdutide. The company added five new products, secured a lucrative Roche license fee, and turned a loss into a RMB\u202f834\u202fm profit.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40308","og_locale":"en_US","og_type":"article","og_title":"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion","og_description":"China\u2011listed Innovent\u202fBiologics (HKG:\u202f1801) posted a 50.6\u202f% YoY revenue jump to RMB\u202f5.95\u202fbn in the first half of 2025, powered by oncology sales and the launch of its GLP\u20111 dual\u2011agonist mazdutide. The company added five new products, secured a lucrative Roche license fee, and turned a loss into a RMB\u202f834\u202fm profit.","og_url":"https:\/\/flcube.com\/?p=40308","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-28T07:40:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2809.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40308#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40308"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion","datePublished":"2025-08-28T07:40:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40308"},"wordCount":238,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40308#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2809.webp","keywords":["Biotech","Finanical Reports","HKG: 1801","Innovent Biologics"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40308#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40308","url":"https:\/\/flcube.com\/?p=40308","name":"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40308#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40308#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2809.webp","datePublished":"2025-08-28T07:40:41+00:00","description":"China\u2011listed Innovent\u202fBiologics (HKG:\u202f1801) posted a 50.6\u202f% YoY revenue jump to RMB\u202f5.95\u202fbn in the first half of 2025, powered by oncology sales and the launch of its GLP\u20111 dual\u2011agonist mazdutide. The company added five new products, secured a lucrative Roche license fee, and turned a loss into a RMB\u202f834\u202fm profit.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40308#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40308"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40308#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2809.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2809.webp","width":1080,"height":608,"caption":"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40308#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent\u202fBiologics Revenue Soars 50% in H1\u202f2025 \u2013 Oncology Growth Fuels GLP\u20111 Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2809.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40308"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40308\/revisions"}],"predecessor-version":[{"id":40311,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40308\/revisions\/40311"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40310"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}